The human CXCR3 receptor was initially identified and cloned in the mid-1990s. In the process of understanding CXCR3, it gradually found that it plays an important role in the process of a variety of diseases, including inflammation, immune diseases, cancer, cardiovascular diseases, central nervous system diseases, etc., which attracted the attention of many researchers. Subsequently, some small molecule inhibitors targeting CXCR3 receptors were also developed. Unfortunately, no CXCR3 inhibitors have been approved for marketing by FDA. Up to now, only one CXCR3 small molecule inhibitor has entered the clinical trial stage, but it has not achieved ideal results in the end. Therefore, there is still much to think about and explore for the development of CXCR3 inhibitors. This article reviews the important role of CXCR3 in various physiological and pathological processes and some small molecule inhibitors of CXCR3.

中文翻译：

---

CXCR3抑制剂的研究进展

人类 CXCR3 受体最初在 20 世纪 90 年代中期被鉴定和克隆。在认识CXCR3的过程中，逐渐发现它在多种疾病的发生过程中发挥着重要作用，包括炎症、免疫疾病、癌症、心血管疾病、中枢神经系统疾病等，引起了很多人的关注。研究人员。随后，一些针对CXCR3受体的小分子抑制剂也被开发出来。不幸的是，FDA尚未批准任何CXCR3抑制剂上市。截至目前，只有一款CXCR3小分子抑制剂进入临床试验阶段，但最终并未取得理想的效果。因此，CXCR3抑制剂的研发还有很多值得思考和探索的地方。本文综述了CXCR3在多种生理病理过程中的重要作用以及CXCR3的一些小分子抑制剂。